Latest:
Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma
Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Raju Kucherlapati, PhD
Latest:
Genomics Studies Opening Up Fresh Options for CRC Research
Raju Kucherlapati, PhD, serves as principal investigator
of a Genome Characterization Center
as part of The Cancer Genome Atlas
program, a National Cancer Institute initiative
aimed at defining the copy number changes and structural aberrations present in many different
cancer types.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
Latest:
Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.
Ralph Boccia, MD
Latest:
Dr. Boccia on Managing Adverse Events With CAR T-Cell Therapy
Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.
ramaswamy
Latest:
Dr. Govindan on the Future of EGFR-Mutant NSCLC
Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).
Ramaswamy Govindan, MD
Latest:
Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC
Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.
Rami D. Komrokji, MD
Latest:
Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS
Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.